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Abstract
Deletion analysis of mouse DNMT1, the primary maintenance methyltransferase in mammals, showed that most of the N-
terminal regulatory domain (amino acid residues 412-1112) is required for its enzymatic activity. Although analysis of
deletion mutants helps to identify regions of a protein sequence required for a particular activity, amino acid deletions can
have drastic effects on protein structure and/or stability. Alternative approaches represented by rational design and
directed evolution are resource demanding, and require high-throughput selection or screening systems. We developed
Regional Frame-shift Mutagenesis (RFM) as a new approach to identify portions required for the methyltransferase activity
of DNMT1 within the N-terminal 89-905 amino acids. In this method, a short stretch of amino acids in the wild-type protein
is converted to a different amino acid sequence. The resultant mutant protein retains the same amino acid length as the
wild type, thereby reducing physical constrains on normal folding of the mutant protein. Using RFM, we identified three
small regions in the amino-terminal one-third of the protein that are essential for DNMT1 function. Two of these regions
(amino acids 124-160 and 341-368) border a large disordered region that regulates maintenance methylation activity. This
organization of DNMT1’s amino terminus suggests that the borders define the position of the disordered region within the
DNMT1 protein, which in turn allows for its proper function.
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Introduction
The mammalian DNA cytosine methyltransferase 1 (DNMT1)
is the enzyme primarily responsible for the accurate perpetuation
of DNA methylation patterns following cell division. DNMT1 is
comprised of a regulatory N-terminal and a catalytic C-terminal
domain, which are linked by a short stretch of Gly-Lys dipeptide
repeats. The C-terminal domain (amino acid residues 1148-1620)
is characterized by the presence of 10 conserved amino acid
motifs, shared with many prokaryotic 5-methyl-cytosine methyl-
transferases [1]. The catalytic center and coenzyme binding site
reside within this domain. The function of the N-terminal domain
is less clear. Based primarily on prominent interacting molecules,
the N-terminal domain can be divided into two separate
subdomains. The more N-terminal subdomain contains the
binding site for the DNA methyltransferase associated protein
DMAP1 (amino acids 12-105) [2], a functional nuclear localization
signal (NLS) (amino acids 191-211), and the binding site for
proliferating cell nuclear antigen PCNA (amino acids 162-171) [3].
Loading of DNMT1 onto hemi-methylated DNA is mediated by
SRA-domain protein UHRF [4]. The SET and RING associated
(SRA) domain of UHRF recognize hemimethylated sites and
directs DNMT1 to these sites [4,5]. The fundamental role of
UHRF in the maintenance of DNA methylation is demonstrated
by the dramatic reduction in global CpG methylation in
homozygous Uhrf-null ES cells and embryos. The C-terminal
domain of DNMT1 contains the replication focus targeting
sequence (RFTS; amino acids 350-609) [6], the zinc-binding
domain, (amino acids 647-693) [7], Bromo Adjacent Homology
domain 2 (BAH2; amino acids 968-1104) [8], and two additional
NLS (amino acids 259-378 and 630-757) [9].
Although the essential enzymatic function of DNMT1 is the
chemical conversion of a hemimethylated DNA substrate into fully
methylated DNA, the regions of the protein regulating this activity
have not been clearly defined. In contrast to prokaryotic
methyltransferases, the C-terminal sub-domain of DNMT1 is
catalytically inactive, and DNMT1 methyltransferase activity
requires a substantial portion of the N-terminal domain. The
direct interaction of one or more N-terminal domains with the C-
terminal domain has been considered a requirement for enzymatic
function [10]. The N-terminal domain may also play an important
role in recognizing hemimethylated substrates. For example
DNMT1-HhaI, a mouse prokaryotic methyltransferase hybrid
containing the intact N-terminus of mouse DNMT1 and most of
the coding sequence of prokaryotic HhaI, has a 2.5-fold preference
for hemimethylated DNA over unmethylated DNA. Such
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preference was not observed for the parental M.HhaI [11].
Moreover, the parental full-length mammalian DNMT1 shows 3-
11 times higher catalytic efficiency for hemimethylated DNA,
suggesting that both C- and N-terminal domains are involved in
distinguishing between hemimethylated and unmethylated DNA.
There have been a number of studies designed to identify the
putative substrate recognition domains within the N-terminal part
of DNMT1. Margot et al. analyzed the methyltransferase activity
of a series of DNMT1 deletion mutants expressed in COS-7 cells
[12]. The activity of each mutant protein was measured in a
whole-cell extract as incorporation of the methyl group from
S-adenosyl-L-methionine into the synthetic substrate poly(dI-dC).
The 59-most part of the analyzed N-terminal region (amino acid
residues 119-425) was found to be dispensable for the methy-
transferase activity. In contrast, deletions within the remainder of
the N-terminal domain (amino acids 426-1090) as well as in the C-
terminal domain (amino acids 1091-1620) showed loss of poly(dI-
dC) methylation. Although this study would suggest that the
substrate recognition requires multiple motifs throughout the N-
terminal and C-terminal domains of DNMT1, the large size of the
analyzed deletions (ranging from amino acids 124-1088) may have
precluded the identification of smaller motifs that are dispensable
for activity.
The findings of subsequent studies on the role of the N-terminal
region in substrate recognition conflicted with those of Margot
et al. [12]. Araujo et al. [13] mapped target recognition to the same
N-terminal region of the enzyme (amino acids 122-417) that was
found dispensable by Margot et al. [12]. The Araujo et al. [13]
findings were refuted by Fatemi et al. [14] who showed that this
region can bind DNA but does not have the ability to distinguish
between methylated and unmethylated DNA. They provided
additional evidence that recognition of hemimethylated DNA is a
property of the more C-terminal Zn-binding and catalytic regions.
Consistent with the report by Fatemi et al. [14], Suetake et al. [15]
reported that the DNA binding activity is located in the N-
terminal amino acids 119-197. This domain does not discriminate
the CG sequence and methylation status. The markedly different
conclusions from these studies might be due to the different in vitro
biochemical assays employed to measure methyltransferase
activity. In none of these studies was methyltransferase activity
assessed in a normal cellular context. In summary, the identifica-
tion of N-terminal sub-domains responsible for target recognition
and enzymatic activity remains controversial.
To more accurately address the requirement of DNMT1 regions
for maintaining DNA methylation, we developed a novel
mutagenesis strategy that allows a rapid and high-throughput
scanning of proteins, such as DNMT1, for which structural insights
into functional regions are not available. This strategy consists of
site-directed mutagenesis to generate mutant cDNAs each encoding
a protein that differs from the wild-type protein for the amino acid
sequence of a short stretch of contiguous amino acids. The rationale
of this strategy is that replacement amino acids that are tolerated at
certain given positions do not play essential roles in protein
structure, stability or activity. Using this approach, we show that, in
contrast to previous studies of DNMT1 function, most of the mutant
proteins generated by this novel approach retain methylating
activity. Only frame-shifts among amino acids 124-160, 386-436,
698-740 and 792-905 abolish DNA methylation activity.
Materials and Methods
Generation of RFM mutants
Dnmt1 RFM mutants were generated by site-directed mutagen-
esis using a plasmid in which the Dnmt1 cDNA is transcribed from
the mouse Pgk1 promoter [16]. Site-directed mutagenesis was
performed with a QuikChange site-directed mutagenesis kit
(Stratagene), according to the manufacturer’s instructions. The
primers used for each point mutation are described in Table S1.
Mutants were confirmed by DNA sequencing.
Plasmid constructs
The pPGK-IRES-p40 plasmid was used to express some RFM
mutant cDNAs from a bicistronic message; this vector has been
described previously [16]. Mutants RFM4A, RFM4B, RFM10,
RFM12A, RFM12B, and RFM19 cDNAs were amplified by PCR
from the Pgk1 expression plasmid [16] using the primers PGKF
(59-ggg gaa ttc tac cgg gta ggg gag g-39) and Mlu-Dnmt1R (59-tct
tcc cga cgc gtc gct agt cct tgg tag cag cct cct ctt tt-39). PCR
reactions were subjected to 25 cycles at 98uC for 30 s, 55uC for
30 s, and 72uC for 20 s, followed by a 10 min extension at 72uC
using KOD DNA polymerase (Novagen). PCR products were gel-
purified, digested with Spe I and Mlu I, and cloned between the
Pgk1 promoter and the IRES sequences of pPGK-IRES-p40. The
integrity of the RFM mutants was verified by DNA sequencing.
Cell cultures and transfections
Mouse embryonic stem (ES) cell lines R1 [17], Dnmt1c/c [18],
and Dnmt1tet/tet [19] were used. The C allele of Dnmt1 disrupts the
C-terminal catalytic domain of the enzyme [18]. Transcription of
the tet allele of Dnmt1 is repressed by the addition of doxycycline to
the culture medium [19]. ES cells were grown in DMEM supple-
mented with 15% fetal bovine serum, 100 mg Streptomycin/ml,
100 U Penicillin/ml, and 1000 U/ml LIF (Chemicon/Millipore).
Cultures were maintained in a humidified chamber in a 5%
CO2/air mixture at 37uC.
Transient transfections of bicistronic pPGK-IRES-p40 plasmids
were carried out with Lipofectamine 2000 (Invitrogen). Cells in
exponential growth were seeded (7.56104) into 24-well plates the
day before transfection. Cells were transfected with 250 ng of
Dnmt1 mutant cDNAs. Forty-eight hours after transfection,
supernatant was collected for measurement of IL-12 p40
concentration [16] and cells were harvested for measurements of
mutant DNMT1 protein expression.
For stable expression in Dnmt1c/c ES cells, 56106 Dnmt1c/c ES
cells in PBS buffer were electroporated with 20 mg each of the
linearized expression vectors encoding RFM mutants along with
2 mg each of linearized pPGK-puro using the BioRad Gene Pulser
II (200 V, 500 mF). Puromycin-resistant clones were picked after
8-10 days of puromycin selection (1 mg/ml), expanded using the
same medium, and examined by immunoblot analysis using the
anti-DNMT1 antibody UPT82 [20]. Puromycin-resistant clones of
Dnmt1c/c ES cells electroporated with RFM4A-IRES-p40 and
RFM12A-IRES-p40 plasmids (plus Pgk-puro) were screened for
p40 expression by an ELISA assay [16]. After puromycin selection
for 8-10 days, eighty clones each were grown in 48-well plates.
After 4 days, the concentration of secreted IL-12 p40 protein in
the medium of the transfected cells was measured using an IL-12
p40 ELISA kit (BioLegend). IL-12 p40 concentration was
measured in duplicate 100-ml samples of culture medium.
For stable expression of Dnmt1tet/tet ES cells, RFM7, RFM8 and
RFM9 mutant cDNAs were first cloned into a modified version of
pEF1/Myc-His A vector (Invitrogen) in which the neomycin-
resistance gene was replaced by the hygromycin-resistance gene.
The expression plasmids were then linearized, electroporated into
Dnmt1tet/tet ES cells, and hygromycin-resistance clones identified
and expanded. For each transfected RFM mutant cDNA, twenty-
four ES cell clones were cultured in the presence of 2 mg/ml
doxycycline for seven days (to repress endogenous DNMT1
RFM of DNMT1 Methyltransferase
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expression) and screened by RT-PCR and immunoblotting for
expression of the mutant Dnmt1 transcript and protein, respec-
tively. Mutant DNMT1 protein was detected using the anti-
DNMT1 UPT82 antibody [20].
Transcription analysis
Expression of RFM7, RFM8 and RFM9 mutants in Dnmt1tet/tet
ES cells was determined by RT-PCR analysis following seven days
of culture of stably transfected ES cell clones with 2 mg/ml
doxycycline. RNA was extracted using the RNAeasy Mini Kit
(Qiagen) and followed by treatment with deoxyribonuclease to
remove any residual genomic DNA. First-strand cDNA was
synthesized using oligodT. The cDNA was amplified in the region
between exons 6 and 17 using Dnmt1-specific oligonucleotides:
Ex6F - GAG TCG GAA GAG GGG AAC TC and Ex17R - CAT
GAA TTG CTT TGG CAC AC. Gel-isolated PCR products
were sequenced using the Ex6F oligonucleotide.
DNA methylation analysis
Southern blot analysis. Genomic DNAs from RFM
mutants were digested with HpaII or MspI (New England
Biolabs), electrophoresed on 1% agarose gels, and transferred to
Genescreen nylon membrane (NEN, Boston, MA). The blots were
hybridized with a 32P-labeled IAP probe [21]. Southern blots were
washed in 2x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium
citrate) with 0.1% sodium dodecylsulfate at room temperature and
with 0.1x SSC with 0.1% sodium dodecylsulfate at 65uC.
Combined bisulfite restriction analysis (COBRA)
Genomic DNA samples were treated with sodium bisulfite using
the EZ DNA methylation Gold kit (Zymo Research, USA)
according to the manufacturer’s recommendations. About 100 ng
each of the converted DNA was amplified with primers designed
for a consensus IAP LTR (GenBank accession no. M17551) [22]
and the skeletal a-actin promoter (accession no. M12347). The
primers used and amplification conditions were the same as
previously described [23,24]. R1 and Dnmt1c/c DNA samples were
used as methylated and unmethylated controls, respectively. To
assess methylation in IAP and skeletal a-actin sequences from
different DNA samples, bisulfite-PCR products were digested with
HpyCH4IV and electrophoresed on polyacrylamide gels.
Bisulfite genomic sequencing
IAP sequences were amplified from bisulfite treated DNA [23],
cloned into TOPO TA vector (Invitrogen) and sequenced. The
fraction of methylated CpGs was determined by dividing the total
number of CpGs observed at eight positions of highly conserved
CpGs in a total of ten sequenced IAP LTRs by 80.
Immunoblotting
ES cells were grown in the absence of mouse embryonic
fibroblast feeders and with 1,000 U of LIF/ml. Cell lysates were
prepared with 10 volumes of RIPA buffer (25 mM Tris-HCl
pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS), denatured by heating at 95uC and then separated by
electrophoresis on SDS-5% polyacrylamide gels. Afterwards, the
electrophoresed proteins were transferred to PVDF membranes
(Immobilon-P Millipore). DNMT1 proteins were detected using
the UPT82 anti-DNMT1 antibody [20]. Membranes were
blocked in 5% dry skim milk in 1X Phosphate Buffered Saline
Tween-20 (PBST) for 1 hour and probed with UPT82 (1:1,000)
overnight at 4uC. Following 5 washes of 5 minutes each in PBST,
the membranes were incubated for 1 hour in donkey anti-rabbit
IgG (Amersham) diluted 1:10,000 in blocking solution. Mem-
branes were washed as above. Bound antibody was detected using
the chemiluminescence detection kit ECL Plus (GE Biosciences).
Immunocytochemistry and microscopy
Cells were fixed with 4% paraformaldehyde (PFA) for 10 min at
room temperature, washed in PBS and blocked for 1 h in blocking
buffer (10% goat serum in PBS). Samples were incubated with the
anti-DNMT1 antibody UPT82 (1:250 dilution) for 1 hour, washed
in PBS and incubated with Texas Red-X goat anti-rabbit IgG
(H+L) (Molecular Probes), and counterstained with DAPI. Images
were acquired using a laser scanning confocal microscope
(FluoView FV1000, Olympus).
Results
Generation of Dnmt1 regional frame-shift cDNA
mutants
To determine which parts of DNMT1 are required for cellular
methyltransferase activity, we generated a collection of cDNAs
expressing DNMT1 mutants that differ from each other in the
sequence of a stretch of amino acids (Table 1). The outline of this
strategy is shown in Figure 1. Using site-directed mutagenesis, a
single nucleotide at a specific position in the cDNA is deleted and
another nucleotide is inserted at another defined position. This
results in a frame-shift of the coding sequence from the site of
nucleotide insertion to the site of deletion (Figure 1). During this
mutagenesis, generation of stop codons is avoided. As the resultant
in-frame insertion-deletion mutations change only a portion of the
protein sequence corresponding to the frame-shift, we named this
strategy as Regional Frame-Shift Mutagenesis (RFM), and the
mutants as RFM mutants. DNMT1 RFM mutants covering most
of the N-terminal regulatory domain of DNMT1 (from the end of
the DMAP1 binding domain to BAH1) were generated
(Figure 2A). Different insertion and deletion sites within a region
were considered and only those that result in a regional frame-shift
of an average stretch of 30 amino acids were synthesized. Stability
of these mutant DNMT1 proteins was tested by transient
transfections into Dnmt1c/c cells devoid of detectable DNMT1
[18] and immunoblotting with the anti-DNMT1 UPT82 antibody
(data not shown). All RFM mutants were expressed in Dnmt1c/c
cells with the exception of RFM10 and RFM19; causes of the lack
of RFM10 and RFM19 expression are addressed below.
Effect of RFM mutants on recovery of DNA methylation
To test the effect of the regional frame-shift mutations on the
enzymatic activity of DNMT1, we assessed the CpG methylation
levels in clones stably expressing RFM mutant proteins, and
compared these levels to genomic methylation in wild-type R1 and
mutant Dnmt1c/c cells. A hypomorphic Dnmt1 allele with a small
fraction (,5%) of wild-type activity maintained approximately
one-third of normal genomic methylation [18,25]. Moreover, ES
cells expressing DNMT1 protein at ,10% of normal concentra-
tion restored genomic methylation in Dnmt1-null ES cells [26]. For
these reasons, we sought to obtain ES cells expressing mutant
proteins at greater than 5% of the wild-type ES-cell DNMT1 level.
Dnmt1c/c ES cells stably expressing different RFM mutants were
obtained by co-electroporation of the mutant cDNA constructs
with a pPGK-puromycin-resistance plasmid. After puromycin
selection for 8-10 days, forty clones for each mutant construct were
screened by immunoblotting. The frequency of clones expressing
mutant DNMT1 proteins at levels $20% of the wild-type (WT)
protein in R1 cells was low, ranging from three to five clones per
mutant. For RFM6-2 and RFM12, only one clone each was
RFM of DNMT1 Methyltransferase
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Table 1. Amino acid modifications in RFM mutants.
Mutant Amino Acid Sequence Position
RFM3 ICPWRTEHTLSLKKPTVVPPTGAGQPGEQKWQTQIA 89-124
WT DLSLENGTHTLTQKANGCPANGSRPTWRAEMADSNR 89-124
RFM4 SPQDPGPSLGDPGEASRTVTPFLKLHLVPWLRGEPPG 124-160
WT RSPRSRPKPRGPRRSKSDSDTLFETSPSSVATRRTTR 124-160
RFM4A SPQDPGPSLGDPGEASRTV 124-142
WT RSPRSRPKPRGPRRSKSDS 124-142
RFM4B RTPFLKLHLVPWLRGEPPG 142-160
WT SDTLFETSPSSVATRRTTR 142-160
RFM5 RPPSRLTSRRAPLNGNPRKSRKRGTRLSRLQRRETRIRNAELL 161-203
WT QTTITAHFTKGPTKRKPKEESEEGNSAESAAEERDQDKKRRVV 161-203
RFM6-1 TQRVVLQLLWRNWKS 203-219
WT DTESGAAAAVEKLEE 203-219
RFM6-2 QREPSWVRKSHVNRKMTTGVF 219-241
WT TAGTQLGPEEPCEQEDDNRSL 219-241
RFM7 PTSHQRAIIEAEIKGGSRQRSKTGNSLGRGRGRKKG 241-276
WT RRHTRELSLRRKSKEDPDREARPETHLDEDEDGKKD 241-276
RFM8 EKEVPDPGASPEIQLPNGDPRKQSQSRL 276-303
WT DKRSSRPRSQPRDPAAKRRPKEAEPEQV 276-303
RFM9 ELQRLPRTETRMRGRRRDEKRHVKNWSHTPFPFRADRS 303-340
WT VAPETPEDRDEDEREEKRRKTTRKKLESHTVPVQSRSE 303-340
RFM10 QKSRSKQKCDPEDQLTKVPRVWPAPRR 341-368
WT RKAAQSKSVIPKINSPKCPECGQHLDD 341-368
RFM10A QKSRSKQKCDPEDH 341-353
WT RKAAQSKSVIPKIN 341-353
RFM10B QLTKVPRVWPAPRRP 354-368
WT HSPKCPECGQHLDDP 354-368
RFM11 RSTSSTLRMLWMNPRC 370-386
WT LKYQQHPEDAVDEPQM 370-386
RFM12 PVRNCPSTTPPRPGLILMKILPCIGSLPSVCTAVAGTCVLSTPVSLRRKL 386-436
WT TSEKLSIYDSTSTWFDTYEDSPMHRFTSFSVYCSRGHLCPVDTGLIEKNV 386-436
RFM12A PVRNCPSTTPPRPGLILI 386-404
WT TSEKLSIYDSTSTWFDTY 386-404
RFM12B MKILPCIGSLPSVCTAVAGTCVLSTPVSLRRKL 404-436
WT YEDSPMHRFTSFSVYCSRGHLCPVDTGLIEKNV 404-436
RFM13 SSTFLGVPKQFMTRIHLWKVVLMAKTSGQSISGGSVA 437-473
WT ELYFSGCAKAIHDENPSMEGGINGKNLGPINQWWLSG 437-473
RFM14 LMVARRCSLASPLHLLNTF 474-493
WT FDGGEKVLIGFSTAFAEYI 474-493
RFM15 RCRRKFTSARLLLSSCKTILMLYMKT 506-532
WT LMQEKIYISKIVVEFLQNNPDAVYED 506-532
RFM16 RSIRLRPLFLLLPLT 532-546
WT LINKIETTVPPSTIN 532-546
RFM17 CEPVHRGLPLTPRPVCSEPGRELRRSQGRY 547-576
WT VNRFTEDSLLRHAQFVVSQVESYDEAKDDD 547-576
RFM18 MRPPSSCLPVC 576-586
WT DETPIFLSPCM 576-586
RFM19 QSPDPFGWCLPGTEASNKARHGCYQGEGQSTHES 586-620
WT RALIHLAGVSLGQRRATRRVMGATKEKDKAPTKA 586-620
RFM20 TLSSQSRLRSMIRRTRRMPL 632-650
WT DTFFSEQIEKYDKEDKENAM 632-650
RFM of DNMT1 Methyltransferase
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obtained. For RFM3, RFM 8, RFM12, RFM13, RFM14,
RFM15, and RFM18 only clones that express relatively low
amounts of DNMT1 were obtained (Figure 2B). The reason for
this is unknown, but may be due to an effect of the mutations on
protein stability.
Genomic DNA samples from ES clones stably expressing an
RFM mutant were obtained after three weeks of continuous cell
culture. Samples were digested with the methylation-sensitive
restriction enzymes HpaII or MspI, a methylation-insensitive
isoschizomer, and analyzed by Southern blot hybridization using
an IAP-LTR probe [21] (Figure 3). The paucity of low-molecular-
weight bands following HpaII digestion of the DNA from the R1
ES cells denotes a high level of DNA methylation of the IAP LTR
repetitive sequences in these cells. The HpaII (H) restriction
pattern in the Dnmt1c/c cells was distinct from that of R1 cells by an
increased hybridization of low-molecular-weight bands, indicating
a strong reduction in DNA methylation. The HpaII digestion
pattern of Dnmt1c/c cells differs slightly from the MspI digestion
pattern, indicating a low level of DNA methylation at the IAP
LTR sequences, probably due to the activity of the de novo
methyltransferases [27]. Introduction of most Dnmt1 RFM cDNA
mutants into Dnmt1c/c cells resulted in a partial restoration of
methylation of bulk repetitive DNA to varying degrees. This was
observed as a substantial increase in the hybridization to high-
molecular-weight DNA, accompanied by a reduction in the
intensity of the low-molecular-weight bands in the HpaII digests
(Figure 3A). These results indicate that Dnmt1c/c ES cells
expressing RFM4, RFM12, RFM23, or RFM24 did not recover
methylation of their IAP LTRs. RFM4, RFM23 and RFM24 cells
expressed approximately wild-type levels of DNMT1 protein
(Figure 2B), indicating that their restoration defect was not likely
due to inadequate protein. For RFM 12 however, we could not
exclude the possibility that its inactivity was due to the low level of
mutant protein expression (Figure 2B).
We also used combined bisulfite restriction analysis (COBRA) to
measure the level of IAP LTR and a-actin promoter methylation
among the DNA samples to identify mutants that fail to maintain
methylation. The single-copy skeletal a-actin promoter is normally
partially methylated both in vivo in day-8.5 mouse embryos [24]
and in mouse ES cells [28]. In these assays, genomic DNA was
treated with sodium bisulfite to convert unmethylated cytosines to
uracils. Methylated cytosines are resistant to such conversion. As a
result, when bisulfite-converted DNA is amplified with primers
specific to a highly conserved IAP LTR sequence and to the
Mutant Amino Acid Sequence Position
RFM21 RSAAAVVSVRSVSSLSVGSARRAKIWL 650-676
WT MKRRRCGVCEVCQQPECGKCKACKDMV 650-676
RFM22 GSLVALDGVSRLASRGGVLTWRL 676-698
WT VKFGGTGRSKQACLKRRCPNLAV 676-698
RFM23 GRRQTTMKRLMMMCQRCHHPKSCIRGRRRSRTRTASPGLGSLL 698-740
WT VKEADDDEEADDDVSEMPSPKKLHQGKKKKQNKDRISWLGQPM 698-740
RFM24 RCSMRTGSALGQTQSWEPPPTPWNCSWWASAKTCSFPTSTARSRSSTKPLLKTGPWR 792-905
EAQTLRPHCLGLRMARLTSSSSGTTRSTQGLNPHPRPSRPRTTSTSSAYLVSGWLS
WT MMFHAHWFCAGTDTVLGATSDPLELFLVGECENMQLSYIHSKVKVIYKAPSENWAME 792-905
GGTDPETTLPGAEDGKTYFFQLWYNQEYARFESPPKTQPTEDNKHKFCLSCIRLAE
doi:10.1371/journal.pone.0009831.t001
Table 1. Cont.
Figure 1. Regional Frame-Shift Mutagenesis. Through site-directed mutagenesis, a mutant cDNA carrying a nucleotide insertion at a defined
site, plus a nucleotide deletion at a second defined site is generated. This results in a frame-shift from the site of the nucleotide insertion to the site of
nucleotide deletion in the mutated cDNA. A library of this type of mutant is generated (Mut1-Mut5). This library encodes proteins that differ from the
wild type in the amino acid sequence of a short segment.
doi:10.1371/journal.pone.0009831.g001
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Figure 2. Regional Frame-Shift Mutagenesis of the DNMT1s protein. (A) Generation of DNMT1 RFM mutants. Top. Subdomains within the
regulatory region of DNMT1. DBD, DMAP1 binding domain; RFTS, replication focus targeting sequence; CXXC, cysteine-rich Zn2+ binding motif; BAH1,
Bromo Adjacent Homology domain 1; Bottom. RFM DNMT1 mutants. Stretch of amino acid sequence changed by RFM is indicated with a gray line.
The RFM mutants and a wild-type Dnmt1 cDNA (WT) were electroporated into Dnmt1c/c ES cells and restoration of DNA methylation was studied. (B)
Western blotting analysis of Dnmt1c/c ES cell clones, each expressing a different RFM mutant. RFM 6-2 is shown separately.
doi:10.1371/journal.pone.0009831.g002
Figure 3. Genomic methylation assay for IAP LTR and a-actin sequences. (A) Southern blots of total DNA extracted from wild-type (R1),
Dnmt1 c/c (c/c), Dnmt1 c/c cells expressing DNMT1 RFM mutants and Dnmt1 c/c cells expressing wild-type DNMT1 (WT). Genomic DNA was digested
with the methylation-sensitive enzyme HpaII (H) and its methylation-insensitive isoschizomer, MspI (M) and hybridized on a Southern blot with an IAP
LTR probe. Hypomethylation of IAP LTR sequences in the Dnmt1c/c cells is indicated by hybridization to low-molecular weight DNA (1.1-kb band) in
the Hpa II digests. (B) Methylation analysis of IAP LTR by COBRA. (C) Methylation analysis of a-actin by COBRA. PCR amplification products represent
unmethylated (U) genomic DNA sequences and their digested products represent methylated (M) genomic sequences; sizes are indicated.
doi:10.1371/journal.pone.0009831.g003
RFM of DNMT1 Methyltransferase
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a2actin promoter, methylated sequences retain CpGs whereas
unmethylated sequences do not contain CpGs. On this basis,
digestion of bisulfite PCR products by HpyCH4IV (recognition site
ACGT) indicates methylation and resistance to digestion indicates
absence of methylation. As shown in Figures 3B and 3C, there is a
greater extent of digestion of the bisulfite-PCR products for both
IAP-LTR and a2actin promoter in R1 cells than in the Dnmt1c/c
cells, consistent with these sequences being methylated in R1 cells
and significantly unmethylated in the Dnmt1c/c cells. When
Dnmt1c/c clones expressing wild type DNMT1 were studied, there
was a clear difference in the extent of digestion of the two
categories of sequences from the Dnmt1c/c cells, indicating a
restoration of methylation in these cells by the wild-type enzyme.
A similar restoration was observed for clones expressing most of
the RFM mutants. Only RFM4, RFM12, RFM23 and RFM24
did not restore genomic methylation. The COBRA assay results
(Figure 3B) agree with the results of the Southern blot
hybridizations (Figure 3A).
To obtain a more quantitative assessment of the level of restored
DNA methylation in cells expressing RFM mutants, we performed
bisulfite genomic sequencing on a subset of RFM mutants to
determine their level of IAP methylation (Table 2). In these
experiments ten IAP alleles for each mutant were analyzed for the
presence of methylated CpGs. In agreement with Southern and
COBRA analysis we observed a significant increase in the number
of methylated CpGs among sequences obtained from clones
containing RFM mutants 9, 11, 15 and 21. This extent of increase
is similar to that observed in Dnmt1c/c cells expressing wild-type
DNMT1. Significant differences among RFM mutants 4, 12, 23,
24 and Dnmt1c/c cells were not observed.
To further characterize RFM mutants that do not restore DNA
methylation, cellular localizations of mutant DNMT1 proteins in
Dnmt1c/c ES cells expressing RFM4, RFM12, RFM23 and RFM24
were determined. Confocal images showed that DNMT1 in
RFM4 is partially retained in the cytoplasm (Figure 4). RFM12
showed a distribution similar to RFM4. DNMT1 in RFM23 and
RFM24 showed only nuclear localization (Figure 4). A concen-
tration gradient of DNMT1 was observed in the nuclei of RFM24,
with a higher concentration of the protein at the nuclear
periphery. We conclude from these observations that the lack of
function of RFM4, RFM12, RFM23 and RFM24 is not due to the
inability to accumulate in the nucleus of ES cells.
Further analysis of faulty RFM mutants
Lack of detectable DNMT1 protein in Dnmt1c/c ES cells
containing RFM10 and RFM19 may be due to degradation of
the mutant Dnmt1 mRNAs or proteins. To explore this possibility,
RFM10 and RFM19 mutant cDNAs were cloned into pPGK-
IRES-p40, an IRES-based bicistronic vector that uses the human
interleukin 12 (IL-12) p40 cDNA as a reporter gene [16]. The
resulting constructs were named pPGK-RFM10-IRES-p40, and
pPGK-RFM19-IRES-p40. The first cistron, encoding the
DNMT1 mutant is translated by a cap-dependent mechanism,
whereas the second cistron encoding IL-12 p40 requires
translation by the IRES. These constructs were transiently
transfected into Dnmt1c/c ES cells. IL-12 p40 and DNMT1
Table 2. Determination of IAP methylation by bisulfite
genomic sequencing.
Cell line % methylated CpG dinucleotidesa,b
Dnmt1c/c 10.0
Dnmt1c/c + WT DNMT1s 47.5
Dnmt1c/c + RFM4 8.3
Dnmt1c/c + RFM9 38.9
Dnmt1c/c + RFM11 32.4
Dnmt1c/c + RFM12 10.1
Dnmt1c/c + RFM15 33.3
Dnmt1c/c + RFM21 42.5
Dnmt1c/c + RFM23 10.1
Dnmt1c/c + RFM24 11.0
aThe percent of methylated CpG dinucleotides for each cell line was determined
by sequencing ten IAP alleles amplified from bisulfite-treated genomic DNA.
Because of their somewhat divergent nature, the IAP LTR sequences contain 7
to 12 CpGs and most of them contain eight CpGs. Therfore, methylation was
assessed at the eight highly conserved CpG dinucleotide positions; CpGs at
these positions in the sequence of the bisulfite-converted (sense) strand was
scored as methylated CpG and TpGs scored as unmethylated CpGs.
bThe efficiency of bisulfite conversion was 100%, based on the absence of CpA,
CpC and CpT dinucleotides in the sequence of the bisulfite-converted (sense)
strand.
doi:10.1371/journal.pone.0009831.t002
Figure 4. Immunolocalization of wild-type (WT) and RFM
mutants expressed in Dnmt1c/c ES cells. R1 and Dnmt1c/c cells are
shown for comparison. DNA column shows DAPI-stained cells. DNMT1
column shows UPT82-stained cells.
doi:10.1371/journal.pone.0009831.g004
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expression were assayed 48 hours after transfection by ELISA and
immunoblotting, respectively. IL-12 p40 was expressed from both
bicistronic mRNAs (Figure 5A). However, no RFM10 and
RFM19 proteins were seen (Figure 5B), presumably due to
degradation of these mutant proteins in ES cells.
RFM mutant 4 (RFM4) and RFM mutant 12 (RFM12) were
expressed in Dnmt1c/c cells, but did not restore genomic
methylation (Figures 2 and 3). To analyze these mutants further,
additional rounds of RFM were performed to divide each mutant
into adjacent and non-overlapping smaller RFM mutants, thus
obtaining sub-mutants 4A and 4B (for RFM4), and sub-mutants
12A and 12B (for RFM12) (see Table 1 for the amino-acid
sequences of the sub-mutants). The stability of these new sub-
mutant proteins was studied using the pPGK-IRES-p40 vector.
pPGK-RFM4A-IRES-p40, pPGK-RFM4B-IRES-p40, pPGK-
RFM12A-IRES-p40, and pPGK-RFM12B-IRES-p40 were tran-
siently transfected in Dnmt1c/c ES cells. After 48 hours, IL-12 p40
was expressed from all bicistronic mRNAs (Figure 5A), whilst
DNMT1 protein expression was observed with RFM4A and
RFM12A, but not with RFM4B and RFM12B (Figure 5B). These
results indicate the RFM4B and RFM12B sub-mutants undergo
degradation. The observation that only poorly expressing RFM12
clones were obtained (Figure 2B) may be related to this presumed
RFM12B degradation. Dnmt1c/c ES cell clones stably expressing
RFM4A and RFM12A were then established, and the level of
CpG methylation of IAP LTR and a-actin promoter sequences
was assessed after three weeks of continuous culture of these
clones. As shown in Figures 5D-5F, these sub-mutant proteins
were unable to maintain genomic methylation.
RFM mutants immediately N- or C-terminal of unstable
RFM10 are expressed as stable proteins that restore methylation
in Dnmt1c/c ES cells. To determine if a portion of RFM10 would
also result in a stable RFM mutant protein, two additional rounds
of RFM were performed to generate sub-mutants RFM10A and
RFM10B. When these cDNAs were transiently expressed from the
Pgk-1 promoter in Dnmt1c/c ES cells, no mutant protein expression
was observed, although transient expression of a control wild-type
Dnmt1 cDNA resulted in robust expression of the wild-type
DNMT1 protein (Figure 5C). These findings indicate that most or
all of DNMT1 defined by RFM10 requires a specific amino acid
sequence for overall DNMT1 stability and function.
Maintenance methylation activity in RFM mutants
The majority of analyzed RFM mutants restored genomic
methylation in Dnmt1c/c ES cells. Three of these mutants, RFM7,
RFM8 and RFM9 were also evaluated for their ability to maintain
already established genomic methylation in Dnmt1tet/tet ES cells
[19]. Dnmt1tet/tet ES cells have genetically engineered TET-OFF
Dnmt1 alleles that are transcriptionally silenced in the presence of
doxycycline. Following transfection with a plasmid expressing the
hygromycin-resistance gene and an RFM mutant, hygromycin-
resistant ES clones were screened for expression of the RFM
mutant protein after seven days of exposure to 2 mg doxycycline,
which extinguished endogenous DNMT1 expression. RNA from
Figure 5. Further characterization of RFM mutants RFM10, RFM19, RFM4 and RFM12. (A) Level of IL-12 p40 protein expression from
Dnmt1c/c ES cells transiently expressing a bicistronic mRNA from the pPGK-IRES-p40 plasmid. cDNAs encoding RFM mutants RFM10, RFM19, RFM4A,
RFM4B, RFM12A and RFM12B were cloned between the PGK promoter and the IRES sequence. RFM4A and RFM4B are sub-frame-shifts of RFM4 and
RFM12A and RFM12B are sub-frame-shift mutants of RFM12. (B) Immunoblot depicting mutant protein expression in transiently transfected Dnmt1c/c
ES cells compared to wild-type R1 and untransfected Dnmt1c/c (c/c) ES cells. (C) Immunoblot depicting mutant protein expression in transiently
transfected Dnmt1c/c ES cells compared to R1 ES cells and to Dnmt1c/c ES cells transiently expressing wild-type DNMT1 protein (WT). (D) Southern blot
of stably expressing RFM4A and RFM12A clones hybridized to an IAP LTR probe. The levels of mutant protein expression in these clones is shown in
Figure 2B. (E) Methylation analysis of IAP LTR sequences in stably expressing ES cells by COBRA. (F) Methylation analysis of the a-actin promoter in
stably expressing ES cells by COBRA.
doi:10.1371/journal.pone.0009831.g005
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each doxycycline-treated clone expressing a DNMT1 mutant (data
not shown) was subjected to RT-PCR analysis (Figure 6A), which
confirmed that only the mutant Dnmt1 was transcribed (Figure 6B).
IAP sequences were methylated at wild-type levels in Dnmt1tet/tet
cells that express RFM7, RFM8 or RFM9 (Figure 6C). Thus, as
Dnmt1tet/tet ES cells switch from expressing wild-type DNMT1 to
expressing just RFM7, RFM8 or RFM9, genomic methylation is
maintained. We conclude from this analysis that restoration of
genomic methylation by an RFM mutant in Dnmt1c/c ES cells
corresponds to the protein’s ability to maintain genomic
methylation in the absence of wild-type DNMT1.
Discussion
RFM analysis of protein structure and function
An accurate and complete dissection of protein structure and
function would require an analysis of the structural and functional
roles of amino acid residues in the protein of interest. This goal is
achieved by comparing the wild-type protein with a mutant
protein carrying amino acid changes. To obtain specific mutant
proteins, a number of different approaches have been engaged.
These fall into the two main categories of rational and random
methods. Rational methods can be applied to a relatively small
class of proteins for which a model of structure-function
relationship has been established [29]. However, these methods
often meet with limited success due to our inability to completely
infer function from structure [30]. Further, these methods cannot
be applied to proteins such as DNMT1 where the relationship
between structure and function is largely unknown. Random
mutagenesis allows the characterization of proteins for which a
structure-function relationship model does not exist. One of the
limitations of random mutagenesis is the necessity to generate a
large collection of protein variants, which in turn requires efficient
and rapid protocols for screening and/or selection of variants with
the desired phenotypes. Therefore, any standard random
mutational approach to analyze DNMT1 function would be
extremely laborious. Deletion analysis of multidomain proteins has
been effectively used to rapidly identify large domains within a
protein that are dispensable for a particular activity. However,
certain deletions may severely affect protein structure or stability,
and therefore preclude the identification of functionally important
amino acid residues [31]. Amino acid substitutions on the other
hand are likely to be better tolerated than deletions in the same
region [22]. These reports suggest that additional methods are
required to rapidly investigate the relationship among protein
sequence, structure and function.
We developed a new mutagenesis strategy in which the
sequence of a short stretch of amino acids in the wild-type protein
is changed by nucleotide insertion and deletion at defined sites.
This results in a frame-shift from the site of nucleotide insertion to
the site of nucleotide deletion. The normal reading frame is
maintained outside these nucleotide changes. Although a mutant
protein obtained by RFM carries several amino acid changes, it
retains the same overall length as the wild-type protein. Because
this method was primarily designed to produce and analyze a
series of frame-shift mutants along the protein’s length, we termed
this strategy Regional Frame-Shift Mutagenesis (RFM). We
anticipate that the majority of such frame-shifts will be better
tolerated than deletions in the same regions and that only a
minority of frame-shifts will disrupt protein function. We
Figure 6. RFM7, RFM8 and RFM9 mutant proteins maintain genomic methylation in Dnmt1tet/tet ES cells. (A) RT-PCR analysis of
exogenous RFM7, RFM8 and RFM9 mRNA expression in Dnmt1tet/tet ES cells treated with doxycycline to extinguish endogenous Dnmt1 expression.
+ indicates presence of reverse transcriptase (RT) in cDNA synthesis reaction; - indicates absence of RT in cDNA synthesis reaction. (B) Sequence
identification of nucleotide deletions (del) and insertions (ins) in RT-PCR products shown in panel A. The corresponding wild-type (WT) sequences
were obtained from RT-PCR products of endogenous Dnmt1 mRNA present in Dnmt1tet/tet ES cells cultured in the absence of doxycycline. (C) COBRA
of IAP LTR sequences in Dnmt1tet/tet ES cells expressing RFM7, RFM8 and RFM9.
doi:10.1371/journal.pone.0009831.g006
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demonstrated the feasibility of this method to identify in situ
portions of DNMT1 required for maintenance methylation
activity within N-terminal amino acids 89-905.
RFM reveals important features of DNMT1 function
Fourteen out of 19 RFM mutants generated within amino acids
89-905 restored methylation in Dnmt1c/c cells, suggesting that most
of the N-terminal region is tolerant of amino acid substitutions. Four
RFM mutants (RFM 4, RFM12, RFM23, and RFM24) did not
restore methylation (Figure 7A). Of these, RFM4 and RFM12
contain frame-shifts from amino acids 124-160 and 386-436
respectively. This result is not in agreement with Margot et al.
who reported that a truncated version of DNMT1 lacking amino
acids 119-425 retained catalytic activity [12]. Therefore, RFM has
resulted in the identification of a short stretch that is functionally
important in a region of DNMT1 that was considered as
dispensable. Previous studies have shown that the RFTS domain
(amino acids 350-609) is indispensable for DNMT1 enzymatic
activity. We generated 11 RFM mutants in this region (RFM9-
RFM19). Of these, only RFM12 (amino acids 386-436) lacks
enzymatic activity. RFM10 (amino acids 341-368) and RFM19
(amino acids 586-620), are transcribed but not expressed, indicating
that these proteins may be abnormally folded and degraded. Since
the remaining RFM mutants are capable of restoring genomic
methylation, our results suggest that the central portion of the RFTS
domain (amino acids 437-586) is tolerant to amino acid substitu-
tions. In agreement with previous reports, RFM23 and RFM24
encompassing BAH1 are defective in maintenance of methylation.
In summary, our approach identified new regions in DNMT1 that
are functionally important, and also ruled out regions that were
previously suggested to be indispensable.
RFM4, RFM10 and RFM12 were studied further with
additional rounds of RFM. RFM4B and RFM12B were
transcribed but not expressed in Dnmt1c/c ES cells, indicating that
these mutants may fail to assume their proper conformation and
therefore be degraded by intracellular proteolytic systems. In
contrast, RFM4A and RFM12A were expressed but defective in
maintenance methylation. RFM10 is also transcribed but not
expressed, and additional rounds of RFM showed that the sub-
mutants RFM10A and RFM10B were also not expressed. These
results indicate that in some instances, exemplified by RFM4 and
RFM12, further RFM analysis can lead to refinements that better
define both functionally and structurally important regions of the
parent wild-type DNMT1 protein. Mutations in RFM4A (amino
acids 124-142) and RFM12A (amino acids 386-404) do not affect
the stability of the mutant protein, but inactivate protein function
(functionally important), whereas mutations in RFM4B (amino
acids 142-160) and RFM12B (amino acids 405-436) result in
degradation of these proteins presumably due to misfolding
(structurally important).
Notably, some of the clones studied expressed very low amounts
of mutant DNMT1 proteins (Figure 2B). RFM13 was observed to
restore methylation in the Dnmt1c/c cells despite the low level of
expression, suggesting that there is no strict relationship between
the levels of expression of DNMT1 with the levels of restoration of
DNA methylation.
Figure 7. Organization of the amino terminus of DNMT1. A. Summary of the effects of regional frame-shift mutagenesis on different regions
of the N-terminal 880 amino acids of DNMT1. Numerals indicate the different RFM mutants. B. Disordered protein prediction score for the amino
terminal portion of DNMT1. The plot was generated using the IUPred disorder prediction algorithm (iupred.enzim.hu); the calculated degree of
disorder from amino acids 89-905 is plotted. Amino acid positions are aligned with the diagram in panel A, and the positions of RFM4 and RFM10
within the disordered region are shown.
doi:10.1371/journal.pone.0009831.g007
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The inactive RFM4 and RFM10 mutants are located in the N-
and C-terminal boundaries of a large predicted disordered region
extending from amino acid,100 to amino acid ,400 (Figure 7B).
Within this disordered region there is a mammal-specific region
that regulates the maintenance of methylation on different DNA
sequences [19]. Most disordered regions interact with protein or
DNA, and may acquire ordered structure upon binding to specific
proteins, DNA sequences or ligands. The conformational
flexibility of disordered regions allows them to interact efficiently
with several different target molecules [32]. In this regard, the
predicted disordered amino-terminal region of DNMT1 binds
several proteins, including Rb and MeCP2 [33] and most likely
interacts with DNA [13]. We speculate that the regions defined by
RFM4 and RFM10 help to define the functionally important
disordered region, possibly by fixing the location of the disordered
region relative to other regions of DNMT1. In addition, RFM10,
RFM12 and RFM19 may identify regions of DNMT1 that are
important for DNMT1 dimerization [34].
Disagreements between some of our results and previously
published data might be explained by the difference in
mutagenesis strategies used to dissect the DNMT1 N-terminal
domain. First, the size of deletions analyzed by Margot et al. [12]
were large, and because of this small regions of DNMT1 that are
dispensable for function were likely not identified. Second, in the
same study, maintenance methyltransferase activity was measured
as the extent of incorporation of methyl groups from S-adenosyl
methionine (SAM) into poly(dI-dC), a synthetic substrate that
interacts with Dnmt1 in a non-physiological manner [23]. Other
studies also used synthetic substrates. For example, Araujo et al.
[13] studied binding of different domains of DNMT1 using solid-
state hemimethylated DNA substrates, and in another study DNA
binding of various domains of DNMT1 was assessed using
unmethylated and hemimethylated oligonucleotides [14]. All of
these studies evaluated DNMT1 action in vitro rather than on
chromosomal DNA in a cellular environment. Lastly, regions
important for the DNMT1 stability cannot be identified in an in
vitro study. Thus, the application of regional frame-shift mutagen-
esis to the study of intracellular function of the DNMT1 protein
yielded some important findings that were not revealed by the
more commonly used genetic and biochemical approaches.
In summary, RFM is a novel and efficient mutagenesis strategy
that enables rapid generation of a large number of mutant proteins
that differ from the wild-type protein in the amino acid sequence
of a short segment. This method is likely to preserve structural and
functional integrity of protein outside the mutated region and also
appears to be an attractive approach to the study of large proteins
(such as DNMT1) in which a model of structure-function
relationship has not been established. RFM mutagenesis will
provide a useful complementary approach for scanning proteins to
quickly identify those regions carrying fundamentally important
information for protein folding, stability or activity.
Supporting Information
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